Abstract:With rapid urbanization and infrastructure investment, wastewater treatment plants (WWTPs) in Chinese cities are putting increased pressure on energy consumption and exacerbating greenhouse gas (GHG) emissions. A carbon footprint is provided as a tool to quantify the life cycle GHG emissions and identify opportunities to reduce climate change impacts. This study examined three mainstream wastewater treatment technologies: Anaerobic-Anoxic-Oxic (A-A-O), Sequencing Batch Reactor (SBR) and Oxygen Ditch, considering four different sludge treatment alternatives for small-to-medium-sized WWTPs. Following the life cycle approach, process design data and emission factors were used by the model to calculate the carbon footprint. Results found that direct emissions of CO2 and N2O, and indirect emissions of electricity use, are significant contributors to the carbon footprint. Although sludge anaerobic digestion and biogas recovery could significantly
OPEN ACCESSWater 2015, 7 919 contribute to emission reduction, it was less beneficial for Oxygen Ditch than the other two treatment technologies due to its low sludge production. The influence of choosing "high risk" or "low risk" N2O emission factors on the carbon footprint was also investigated in this study. Oxygen Ditch was assessed as "low risk" of N2O emissions while SBR was "high risk". The carbon footprint of A-A-O with sludge anaerobic digestion and energy recovery was more resilient to changes of N2O emission factors and control of N2O emissions, though process design parameters (i.e., effluent total nitrogen (TN) concentration, mixed-liquor recycle (MLR) rates and solids retention time (SRT)) and operation conditions (i.e., nitrite concentration) are critical for reducing carbon footprint of SBR. Analyses of carbon footprints suggested that aerobic treatment of sludge not only favors the generation of large amounts of CO2, but also the emissions of N2O, so the rationale of reducing aerobic treatment and maximizing anaerobic treatment applies to both wastewater and sludge treatment for reducing the carbon footprint, i.e., the annamox process for wastewater nutrient removal and the anaerobic digestion for sludge treatment.
Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified gene target from prostate cancer, breast cancer, and gastric cancer. However, functions of STEAP1 in lung adenocarcinoma (LUAD) are still unknown. In the present study, we explored the molecular and cellular mechanisms of STEAP1 in LUAD. Western blot and Q-PCR were conducted to detect the protein and mRNA expressions respectively. The cell proliferation was tested by CCK8 assay. The effects of STEAP1 on the metastasis and epithelial–mesenchymal transition (EMT) of LUAD were evaluated by EdU assay, wound healing assay, and transwell migratory assay. H1650, H358, HCC827, H1299, H23, A549, H1693 were selected as human LUAD cell lines in the study. Results have shown that STEAP1 expression was up-regulated in LUAD cells compared with normal lung epithelial cells. Knockdowning of STEAP1 suppressed the proliferation, migration, and invasion of LUAD epithelial cells. Importantly, after comparing the proliferation, migration, and invasion of LUAD to the corresponding control groups treated in STAT3 inhibitor ADZ1480, we found that STEAP1 regulates EMT via Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. In conclusion, STEAP1 can serve as a therapeutic target, and it may have important clinical implications for LUAD treatment.
Electrocoagulation-flotation (ECF) is a new technology for algae harvesting with higher collection efficiency and lower energy consumption, as compared to flocculation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.